Expertise in
10
conditions

Dr. Aditya Bardia

Hematology | Oncology
The Regents Of The University Of California
2336 Santa Monica Blvd, 
Santa Monica, CA 
Clinical Trials:Currently Recruiting for 4 Trials
Offers Telehealth
Expertise in
10
conditions
The Regents Of The University Of California
2336 Santa Monica Blvd, 
Santa Monica, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aditya Bardia is a Hematologist and an Oncologist in Santa Monica, California. Dr. Bardia is highly rated in 10 conditions, according to our data. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, Inflammatory Breast Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 267 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2336 Santa Monica Blvd, Santa Monica, CA 90404
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404

Additional Areas of Focus

Dr. Bardia has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab Govitecan, Pembrolizumab
Study Phase: Phase 2
A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Sacituzumab govitecan
Study Phase: Phase 2
Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer
Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Talazoparib, Sacituzumab Govitecan
Study Phase: Phase 1/Phase 2
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting
Enrollment Status: Recruiting
Publish Date: July 17, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Anastrozole, Trastuzumab Deruxtecan
Study Phase: Phase 2
Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib,With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)
Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib,With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drugs: Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib
Study Phase: Phase 1
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER).
Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER).
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 2
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer
A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer
Enrollment Status: Terminated
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, PDR001, Fulvestrant
Study Phase: Phase 1
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2025
Intervention Type: Drug, Procedure
Study Drugs: T-DM1, Pertuzumab
Study Phase: Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function
An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function
Enrollment Status: Withdrawn
Publish Date: August 01, 2023
Intervention Type: Drug
Study Drugs: Neratinib, Fulvestrant
Study Phase: Phase 2
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: March 31, 2023
Intervention Type: Drug
Study Drug: LY3484356
Study Phase: Phase 1
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Enrollment Status: Completed
Publish Date: August 01, 2022
Intervention Type: Drug
Study Drugs: Ribociclib, T-DM1, Trastuzumab, Fulvestrant
Study Phase: Phase 1/Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 18 Less Clinical Trials

265 Total Publications

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates.
Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 29, 2025
Similar Doctors
Expertise in
28
conditions
Dr. Sant P. Chawla
Oncology | Hematology
Expertise in
28
conditions
Dr. Sant P. Chawla
Oncology | Hematology
2811 Wilshire Boulevard, Suite 414, 
Santa Monica, CA 
 (0.5 miles away)
310-552-9999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is highly rated in 28 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is currently accepting new patients.

Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
9201 W Sunset Blvd, 
West Hollywood, CA 
 (6.3 miles away)
310-623-1222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Berenson is a Hematologist and an Oncologist in West Hollywood, California. Dr. Berenson is highly rated in 7 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Bone Tumor, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia, and Vertebroplasty.

Bartosz Chmielowski
Expertise in
31
conditions
Dr. Bartosz Chmielowski
Hematology | Oncology
Expertise in
31
conditions
Dr. Bartosz Chmielowski
Hematology | Oncology

The Regents Of The University Of California

900 Weyburn Place, Suite 14 171, 
Los Angeles, CA 
 (2.6 miles away)
310-825-8173
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bartosz Chmielowski is a Hematologist and an Oncologist in Los Angeles, California. Dr. Chmielowski is highly rated in 31 conditions, according to our data. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Metastatic Uveal Melanoma, Vulvectomy, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bardia's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile